Stocks and Investing
Stocks and Investing
Wed, December 20, 2017
[ 12:00 AM ] - United States, WOPRAI
Tue, December 19, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, December 18, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Christopher Raymond Initiated (AKBA) at Buy and Held Target at $26 on, Dec 18th, 2017
Christopher Raymond of Piper Sandler, Initiated "Akebia Therapeutics, Inc." (AKBA) at Buy and Held Target at $26 on, Dec 18th, 2017.
Christopher has made no other calls on AKBA in the last 4 months.
There are 2 other peers that have a rating on AKBA. Out of the 2 peers that are also analyzing AKBA, 0 agree with Christopher's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Christopher
- Robert Hazlett of "BTIG" Initiated at Strong Buy and Held Target at $30 on, Thursday, December 7th, 2017
- Difei Yang of "Mizuho" Initiated at Strong Buy and Held Target at $24 on, Thursday, October 5th, 2017
Contributing Sources